Outcomes of second allogeneic stem cell transplantation and anti‐relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis

Second allogeneic stem cell transplantation (allo‐SCT2) represents a rescue option for selected patients (pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML). Still, relapse rates post‐allo‐SCT2 remain high and effective anti‐relapse strategies and predictive biomarkers remain to be defined. We here analyzed a cohort of 41 AML patients (pts) undergoing allo‐SCT2 in our center. Allo‐SCT2 induced a third hematologic complete remission (CR) in 37 pts, at costs of a 36% non‐relapse mortality rate. Furthermore, 19 pts eventually relapsed post allo‐SCT2. Addressing relapse after allo‐SCT2, 14 pts (74%) underwent cell‐based anti‐relapse strategies, including third allogeneic transplantation (allo‐SCT3; 3/14), donor lymphocyte infusions (DLIs) combined with either 5‐azacytidin and venetoclax (4/14) or chemotherapeutic agents (7/14). Notably, six of seven pts (86%) who received either allo‐SCT3 or a combination therapy of DLIs, 5‐azacytidine and venetoclax achieved CR despite poor cytogenetics post‐allo‐SCT2 (e.g., TP53). Finally, 11 of 41 pts were alive at the last follow‐up (seven CR2, three CR3, one partial remission) resulting in estimated 2‐ and 5‐year overall survival of 35% and 25%, respectively.

[1]  M. Konopleva,et al.  Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions , 2020, Frontiers in Oncology.

[2]  E. Shumilov,et al.  Experiences with Next-Generation Sequencing in Relapsed Acute Myeloid Leukemia: A Patient Case Series , 2020, Mediterranean journal of hematology and infectious diseases.

[3]  E. Shumilov,et al.  Current concepts and future directions for hemato-oncologic diagnostics. , 2020, Critical reviews in oncology/hematology.

[4]  E. Shumilov,et al.  Clinical potential of introducing next‐generation sequencing in patients at relapse of acute myeloid leukemia , 2020, Hematological oncology.

[5]  C. Vigil,et al.  Hypomethylating Agents and Low-Dose Venetoclax for Relapse Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation , 2020 .

[6]  M. Tallman,et al.  Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. , 2020, Haematologica.

[7]  C. Craddock,et al.  The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience , 2019, British journal of haematology.

[8]  N. Kröger,et al.  Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT , 2019, Blood Cancer Journal.

[9]  R. Larson,et al.  Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. , 2019, The New England journal of medicine.

[10]  U. Amstutz,et al.  Critical evaluation of current molecular MRD strategies including NGS for the management of AML patients with multiple mutations , 2019, Hematological oncology.

[11]  C. Craddock,et al.  Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT , 2019, Leukemia.

[12]  M. Kharfan-Dabaja,et al.  What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia? , 2019, Bone Marrow Transplantation.

[13]  Sarah E. Dorff,et al.  FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation , 2019, Clinical Cancer Research.

[14]  R. Larson,et al.  Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant , 2019, Experimental Hematology & Oncology.

[15]  A. Kohlmann,et al.  Current status and trends in the diagnostics of AML and MDS. , 2018, Blood reviews.

[16]  R. Mahfouz,et al.  Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation , 2018, Bone Marrow Transplantation.

[17]  M. Labopin,et al.  Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse , 2018, JAMA oncology.

[18]  G. Marcucci,et al.  Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia , 2018, Haematologica.

[19]  E. Holler,et al.  EBMT—NIH—CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment , 2018, Bone Marrow Transplantation.

[20]  M. Konopleva,et al.  Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies , 2018, American journal of hematology.

[21]  C. Bloomfield,et al.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.

[22]  I. Flinn,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[23]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[24]  R. Claus,et al.  Decitabine (DAC) in Combination with Donor Lymphocyte Infusions (DLIs) Can Induce Remissions of Overt Aml Relapses after Allogeneic Transplantation , 2016 .

[25]  J. Esteve,et al.  Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT , 2016, Bone Marrow Transplantation.

[26]  R. Vij,et al.  Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  J. Sierra,et al.  Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  N. Kröger,et al.  Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT , 2015, Bone Marrow Transplantation.

[29]  M. Lübbert,et al.  5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft , 2015, Bone Marrow Transplantation.

[30]  Y. Ebihara,et al.  Third allogeneic stem cell transplantation (SCT) using unrelated cord blood for relapsed acute leukemia after second allogeneic SCT , 2015, International Journal of Hematology.

[31]  M. Norkin,et al.  Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  N. Kröger,et al.  Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Schlenk,et al.  Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. , 2013, Leukemia research.

[34]  C. Schmoor,et al.  Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML , 2013, Bone Marrow Transplantation.

[35]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[36]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  M. Tallman,et al.  Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant , 2004, Bone Marrow Transplantation.

[38]  M. Labopin,et al.  Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[40]  W. Hiddemann,et al.  Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. , 1995, Blood.